158 related articles for article (PubMed ID: 32282437)
1. Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes.
Santella C; Yin H; Hicks BM; Yu OHY; Bouganim N; Azoulay L
Epidemiology; 2020 Jul; 31(4):559-566. PubMed ID: 32282437
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.
Hicks BM; Yin H; Yu OH; Pollak MN; Platt RW; Azoulay L
BMJ; 2016 Oct; 355():i5340. PubMed ID: 27797785
[TBL] [Abstract][Full Text] [Related]
3. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
Pradhan R; Yu OHY; Platt RW; Azoulay L
Diabet Med; 2024 Apr; 41(4):e15248. PubMed ID: 37876318
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.
Douros A; Filion KB; Yin H; Yu OH; Etminan M; Udell JA; Azoulay L
Diabetes Care; 2018 Nov; 41(11):2330-2338. PubMed ID: 30150234
[TBL] [Abstract][Full Text] [Related]
5. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
[TBL] [Abstract][Full Text] [Related]
7. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
8. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
[TBL] [Abstract][Full Text] [Related]
9. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
10. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
11. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
[TBL] [Abstract][Full Text] [Related]
12. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK.
Weiss T; Yang L; Carr RD; Pal S; Sawhney B; Boggs R; Rajpathak S; Iglay K
BMJ Open Diabetes Res Care; 2022 Jan; 10(1):. PubMed ID: 35101924
[TBL] [Abstract][Full Text] [Related]
13. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
[No Abstract] [Full Text] [Related]
14. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
Herrera Comoglio R; Vidal Guitart X
Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
[TBL] [Abstract][Full Text] [Related]
15. Newer GLP-1 receptor agonists and obesity-diabetes.
Brown E; Cuthbertson DJ; Wilding JP
Peptides; 2018 Feb; 100():61-67. PubMed ID: 29412833
[TBL] [Abstract][Full Text] [Related]
16. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB;
BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881
[TBL] [Abstract][Full Text] [Related]
18. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.
Liu BD; Udemba SC; Liang K; Tarabichi Y; Hill H; Fass R; Song G
Gut; 2024 Jan; 73(2):246-254. PubMed ID: 37739778
[TBL] [Abstract][Full Text] [Related]
19. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
20. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
